Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg, the company announced through an exchange filing.
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).
Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg had annual sales of USD 105 mn in the United States (IQVIA MAT May 2023).
The group now has 374 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
NCVT ITI Result 2025 Declared At skillindiadigital.gov.in; Direct Link Here
'You Are My Final Hope': The Bengal Files Producer Pallavi Joshi Writes An Open Letter To President Of India As Theatres In West Bengal Refuse To Screen Her Film
Maharashtra Cancels Authorized Service Providers For Online Leave & License Registration
‘2 Numberi’: Pakistan’s Punjab CM Maryam Nawaz Trolled For Claiming To Have Installed Portable Washrooms In Flood-Affected Areas; Netizens Expose ‘Scam’
